Benjamin J. Zeskind insider trades: Immuneering (IMRX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Benjamin reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | IMRX | ↑ Buy | 2,400 | $4.56 | $11K | Direct | Jun 24, 2026 (1d) |
| Jul 2, 2025 | IMRX | ↑ Buy | 10,000 | $3.49 | $35K | Direct | Jul 3, 2025 (1d) |
| Jun 18, 2025 | IMRX | ↑ Buy | 21,000 | $2.39 | $50K | Direct | Jun 20, 2025 (2d) |
| Mar 19, 2024 | IMRX | ↑ Buy | 20,000 | $2.77 | $55K | Direct | Mar 19, 2024 (0d) |
| Mar 23, 2022 | IMRX | ↑ Buy | 3,000 | $8.02 | $24K | Direct | Mar 24, 2022 (1d) |
| Sep 13, 2021 | IMRX | ↑ Buy | 2,083 | $22.87 | $48K | Direct | Sep 14, 2021 (1d) |
| Aug 3, 2021 | IMRX | ↑ Buy | 2,098 | $15.00 | $31K | Direct | Aug 4, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IMRX insiders
Open-market trades in the last 12 months
About Benjamin J. Zeskind's insider trades
Benjamin J. Zeskind is President and CEO at Immuneering (IMRX). Since Aug 3, 2021, Benjamin has reported 7 open-market purchases worth $254K and no sales on SEC Form 4. In the last 12 months: 1 buy ($11K).
Their filings also include grants and awards (5 filings), option exercises (3 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.